Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Nyvepria Resubmission Journey: From FDA CRL to Approval 

Categories: Orphan & Rare Diseases / Antibody Drug Conjugates / Priority Review
85

Hello Regulatory Scientists, 

Today, let’s explore the journey of Nyvepria (pegfilgrastim-apgf) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Nyvepria (pegfilgrastim-apgf) 
Mechanism of Action: Granulocyte colony-stimulating factor (G-CSF) biosimilar, which stimulates the production of white blood cells to reduce the risk of infection in patients undergoing chemotherapy 
Indication: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs 
Initial Submission Date: October 2019 

The Complete Response Letter (CRL) 

CRL Date: June 2020 
CRL Concerns: 

  1. Manufacturing Process: The FDA raised concerns about the quality and consistency of the drug’s manufacturing process. 
  1. Analytical Comparability: Request for additional analytical data to demonstrate comparability between Nyvepria and the reference product. 
  1. Risk Management Plan: Need for a robust risk management plan to monitor and mitigate potential adverse effects. 

Resubmission Strategy 

Pfizer, the company behind Nyvepria, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Manufacturing Process Improvements: Made significant enhancements to the manufacturing process to ensure consistency and quality. 
  1. Enhanced Quality Control Measures: Established stricter quality control measures to address any potential issues with the manufacturing process. 
  1. Additional Analytical Data: Conducted further studies and analyses to provide more robust data demonstrating comparability between Nyvepria and the reference product. 
  1. Risk Management Plan: Developed a detailed risk management plan, including monitoring guidelines and patient education materials. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: August 2020 

Outcome 

Approval Date: June 2020 
Nyvepria was approved to decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs, providing a new and effective biosimilar option. 

Lessons Learned 

The journey of Nyvepria from CRL to approval highlights several key lessons for drug developers: 

  1. Manufacturing Process Improvements: Ensuring the quality and consistency of the manufacturing process is crucial. Proactive improvements and rigorous quality control measures can prevent setbacks. 
  1. Comprehensive Data Collection: Providing extensive analytical data to support the comparability of biosimilars is essential to addressing FDA concerns. 
  1. Effective Risk Management: Developing and implementing a detailed risk management plan can help mitigate potential adverse effects and ensure patient safety. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the drug’s production. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Nyvepria case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including manufacturing processes and analytical data, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Nyvepria resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

image 1
Picture of Asad Khan
Asad Khan